130 related articles for article (PubMed ID: 34121397)
1. Discovery and Characterization of Benzimidazole Derivative XY123 as a Potent, Selective, and Orally Available RORγ Inverse Agonist.
Wu X; Shen H; Zhang Y; Wang C; Li Q; Zhang C; Zhuang X; Li C; Shi Y; Xing Y; Xiang Q; Xu J; Wu D; Liu J; Xu Y
J Med Chem; 2021 Jun; 64(12):8775-8797. PubMed ID: 34121397
[TBL] [Abstract][Full Text] [Related]
2. Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable RORγ Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer.
Zhang Y; Wu X; Xue X; Li C; Wang J; Wang R; Zhang C; Wang C; Shi Y; Zou L; Li Q; Huang Z; Hao X; Loomes K; Wu D; Chen HW; Xu J; Xu Y
J Med Chem; 2019 May; 62(9):4716-4730. PubMed ID: 30964293
[TBL] [Abstract][Full Text] [Related]
3. Discovery and pharmacological characterization of 1,2,3,4-tetrahydroquinoline derivatives as RORγ inverse agonists against prostate cancer.
Wu XS; Luo XY; Li CC; Zhao XF; Zhang C; Chen XS; Lu ZF; Wu T; Yu HN; Peng C; Hu QQ; Shen H; Xu Y; Zhang Y
Acta Pharmacol Sin; 2024 May; ():. PubMed ID: 38698214
[TBL] [Abstract][Full Text] [Related]
4. Identification of N-phenyl-2-(N-phenylphenylsulfonamido)acetamides as new RORγ inverse agonists: Virtual screening, structure-based optimization, and biological evaluation.
Song Y; Xue X; Wu X; Wang R; Xing Y; Yan W; Zhou Y; Qian CN; Zhang Y; Xu Y
Eur J Med Chem; 2016 Jun; 116():13-26. PubMed ID: 27043267
[TBL] [Abstract][Full Text] [Related]
5. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
Handratta VD; Vasaitis TS; Njar VC; Gediya LK; Kataria R; Chopra P; Newman D; Farquhar R; Guo Z; Qiu Y; Brodie AM
J Med Chem; 2005 Apr; 48(8):2972-84. PubMed ID: 15828836
[TBL] [Abstract][Full Text] [Related]
6. Discovery of biaryl carboxylamides as potent RORγ inverse agonists.
Chao J; Enyedy I; Van Vloten K; Marcotte D; Guertin K; Hutchings R; Powell N; Jones H; Bohnert T; Peng CC; Silvian L; Hong VS; Little K; Banerjee D; Peng L; Taveras A; Viney JL; Fontenot J
Bioorg Med Chem Lett; 2015 Aug; 25(15):2991-7. PubMed ID: 26048806
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 2-(Ortho-Substituted Benzyl)-Indole Derivatives as Potent and Orally Bioavailable RORγ Agonists with Antitumor Activity.
Lu B; Liu D; Gui B; Gou J; Dong H; Hu Q; Feng J; Mao Y; Shen X; Wang S; Zhang C; Shen R; Yan Y; Chen L; Wang H; Li D; Zhang J; Zhang M; Zhang R; Bai C; He F; Tao W; Liu S
J Med Chem; 2021 Oct; 64(20):14983-14996. PubMed ID: 34643383
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)-
Wu Y; Wang B; Wang J; Qi S; Zou F; Qi Z; Liu F; Liu Q; Chen C; Hu C; Hu Z; Wang A; Wang L; Wang W; Ren T; Cai Y; Bai M; Liu Q; Liu J
J Med Chem; 2019 Jul; 62(13):6083-6101. PubMed ID: 31250638
[TBL] [Abstract][Full Text] [Related]
9. Discovery of a novel RORγ antagonist with skin-restricted exposure for topical treatment of mild to moderate psoriasis.
Liu S; Liu D; Shen R; Li D; Hu Q; Yan Y; Sun J; Zhang F; Wan H; Dong P; Feng J; Zhang R; Li J; Zhang L; Tao W
Sci Rep; 2021 Apr; 11(1):9132. PubMed ID: 33911101
[TBL] [Abstract][Full Text] [Related]
10. Annulation reaction enables the identification of an exocyclic amide tricyclic chemotype as retinoic acid Receptor-Related orphan receptor gamma (RORγ/RORc) inverse agonists.
Marcoux D; Bertrand MB; Weigelt CA; Yip S; Galella M; Park H; Wu DR; Wang J; Yarde M; Cvijic ME; Li S; Hynes J; Tino JA; Zhao Q; Dhar TGM
Bioorg Med Chem Lett; 2020 Oct; 30(19):127466. PubMed ID: 32763309
[TBL] [Abstract][Full Text] [Related]
11. Design, Synthesis, and Biological Evaluation of 1-(Indolizin-3-yl)ethan-1-ones as CBP Bromodomain Inhibitors for the Treatment of Prostate Cancer.
Xiang Q; Wang C; Wu T; Zhang C; Hu Q; Luo G; Hu J; Zhuang X; Zou L; Shen H; Wu X; Zhang Y; Kong X; Liu J; Xu Y
J Med Chem; 2022 Jan; 65(1):785-810. PubMed ID: 34962793
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 1-{4-[3-fluoro-4-((3s,6r)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmethyl)-phenyl]-piperazin-1-yl}-ethanone (GNE-3500): a potent, selective, and orally bioavailable retinoic acid receptor-related orphan receptor C (RORc or RORγ) inverse agonist.
Fauber BP; René O; Deng Y; DeVoss J; Eidenschenk C; Everett C; Ganguli A; Gobbi A; Hawkins J; Johnson AR; La H; Lesch J; Lockey P; Norman M; Ouyang W; Summerhill S; Wong H
J Med Chem; 2015 Jul; 58(13):5308-22. PubMed ID: 26061388
[TBL] [Abstract][Full Text] [Related]
13. Discovery of LYC-55716: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor-γ (RORγ) Agonist for Use in Treating Cancer.
Aicher TD; Van Huis CA; Hurd AR; Skalitzky DJ; Taylor CB; Beleh OM; Glick G; Toogood PL; Yang B; Zheng T; Huo C; Gao J; Qiao C; Tian X; Zhang J; Demock K; Hao LY; Lesch CA; Morgan RW; Moisan J; Wang Y; Scatina J; Paulos CM; Zou W; Carter LL; Hu X
J Med Chem; 2021 Sep; 64(18):13410-13428. PubMed ID: 34499493
[TBL] [Abstract][Full Text] [Related]
14. New Therapeutic Target for Prostate Cancer.
Cancer Discov; 2016 Jun; 6(6):OF6. PubMed ID: 27091858
[TBL] [Abstract][Full Text] [Related]
15. Discovery of 2,6-difluorobenzyl ether series of phenyl ((R)-3-phenylpyrrolidin-3-yl)sulfones as surprisingly potent, selective and orally bioavailable RORγt inverse agonists.
Duan JJ; Jiang B; Lu Z; Stachura S; Weigelt CA; Sack JS; Khan J; Ruzanov M; Wu DR; Yarde M; Shen DR; Zhao Q; Salter-Cid LM; Carter PH; Murali Dhar TG
Bioorg Med Chem Lett; 2020 Oct; 30(19):127441. PubMed ID: 32736080
[TBL] [Abstract][Full Text] [Related]
16. Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer.
Han X; Zhao L; Xiang W; Qin C; Miao B; McEachern D; Wang Y; Metwally H; Wang L; Matvekas A; Wen B; Sun D; Wang S
J Med Chem; 2021 Sep; 64(17):12831-12854. PubMed ID: 34431670
[TBL] [Abstract][Full Text] [Related]
17. Discovery of the First-in-Class RORγ Covalent Inhibitors for Treatment of Castration-Resistant Prostate Cancer.
Fang W; Zheng J; Deng L; An Y; Rong D; Wei J; Xiong XF; Wang J; Wang Y
J Med Chem; 2024 Jan; 67(2):1481-1499. PubMed ID: 38227771
[TBL] [Abstract][Full Text] [Related]
18. Discovery and Optimization of a Series of Sulfonamide Inverse Agonists for the Retinoic Acid Receptor-Related Orphan Receptor-α.
Doebelin C; He Y; Campbell S; Nuhant P; Kumar N; Koenig M; Garcia-Ordonez R; Chang MR; Roush WR; Lin L; Kahn S; Cameron MD; Griffin PR; Solt LA; Kamenecka TM
Med Chem; 2019; 15(6):676-684. PubMed ID: 30799793
[TBL] [Abstract][Full Text] [Related]
19. Discovery of phenoxyindazoles and phenylthioindazoles as RORγ inverse agonists.
Ouvry G; Bouix-Peter C; Ciesielski F; Chantalat L; Christin O; Comino C; Duvert D; Feret C; Harris CS; Lamy L; Luzy AP; Musicki B; Orfila D; Pascau J; Parnet V; Perrin A; Pierre R; Polge G; Raffin C; Rival Y; Taquet N; Thoreau E; Hennequin LF
Bioorg Med Chem Lett; 2016 Dec; 26(23):5802-5808. PubMed ID: 27815118
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel pyrazole-containing benzamides as potent RORγ inverse agonists.
Wang T; Banerjee D; Bohnert T; Chao J; Enyedy I; Fontenot J; Guertin K; Jones H; Lin EY; Marcotte D; Talreja T; Van Vloten K
Bioorg Med Chem Lett; 2015 Aug; 25(15):2985-90. PubMed ID: 26048789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
